GSK won U.S. approval for its second lung cancer drug from the Nuvalent deal
The FDA granted accelerated approval to neladalkib, sold as Nelkarmi, for ALK-positive non-small cell lung cancer
We haven't written up this one. Quartz has the full story — the link below goes straight to it.
Also reported by 2 other outlets
- GSK wins FDA nod for lung cancer therapy added from Nuvalent buyout seekingalpha.com
- GSK wins FDA approval for lung cancer drug Nelkarmi investing.com